CAI trades 14.2% above Wall Street's consensus target of $28.50.
Last 12 months price action with 12-month analyst target path
The base valuation assumes CAI achieves its forward estimates and maintains a stable P/E multiple of 275.9x. This scenario reflects the blended consensus of 8 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 8, 2026, Caris Life Sciences, Inc. (CAI) has a Wall Street consensus price target of $28.50, based on estimates from 8 covering analysts. With the stock currently trading at $33.22, this represents a potential downside of -14.2%. The company has a market capitalization of $9.39B.
Analyst price targets range from a low of $22.00 to a high of $38.00, representing a 56% spread in expectations. The median target of $27.00 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 7 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, CAI trades at a trailing P/E of -17.9x and forward P/E of 275.9x. Analysts expect EPS to grow -67.6% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 EXASExact Sciences Corporation | $20.0B | $104.91 | $92.95 | -11.4% | Buy | 582.8x | 41 |
 ILMNIllumina, Inc. | $34.3B | $226.54 | $252.73 | +11.6% | Buy | 42.0x | 50 |
 NTRANatera, Inc. | $56.0B | $391.03 | $386.00 | -1.3% | Buy | — | 28 |
 GHGuardant Health, Inc. | $22.4B | $168.58 | $203.40 | +20.7% | Buy | — | 31 |
 FDMT4D Molecular Therapeutics, Inc. | $642M | $12.28 | $29.67 | +141.6% | Buy | — | 14 |
 CDNACareDx, Inc | $4.4B | $85.86 | $75.25 | -12.4% | Buy | 66.0x | 14 |
 PACBPacific Biosciences of California, Inc. | $792M | $2.55 | $1.93 | -24.3% | Buy | — | 18 |
 CERTCertara, Inc. | $1.7B | $11.09 | $8.50 | -23.4% | Hold | 32.6x | 17 |
 ACMRACM Research, Inc. | $2.8B | $44.43 | $113.20 | +154.8% | Buy | 20.1x | 10 |
 TMOThermo Fisher Scientific Inc. | $262.4B | $706.16 | $694.27 | -1.7% | Buy | 27.9x | 43 |
Quick answers to the most common questions about buying CAI stock.
CAI's consensus price target is $28.5, -14.2% below the current price of $33.22. The 8 analysts tracking CAI see downside risk at present valuations.
CAI has a consensus rating of "Buy" based on 8 Wall Street analysts. The rating breakdown is predominantly bullish, with 7 Buy/Strong Buy ratings. The consensus 12-month price target of $28.5 implies -14.2% downside from current levels.
At a forward P/E of 275.9136x, CAI trades at a premium valuation. The consensus price target of $28.5 (-14.2% downside) suggests analysts may view current valuations as stretched.
The most bullish Wall Street analyst has a price target of $38 for CAI, while the most conservative target is $22. The consensus of $28.5 represents the median expectation. These targets typically reflect 12-month expectations.
CAI is moderately covered, with 8 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 7 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CAI stock forecast based on 8 Wall Street analysts shows a consensus price target of $28.5, with estimates ranging from $22 (bear case) to $38 (bull case). The median consensus rating is "Buy".
CAI trades at a forward P/E ratio of 275.9x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Analysts are cautious on CAI, with 0 Sell ratings and a price target of $28.5 (-14.2% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CAI analyst price targets range from $22 to $38, a 56% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $28.5 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.